The Swiss team isolated a series of monoclonal antibodies from individuals who were protected from one of these experimental vaccines (Sanaria PfSPZ Vaccine) and found that the most
effective antibodies recognized a distinct region within the surface protein of the sporozoites that has not been considered in malaria vaccines so far.